Tranzyme’s pipeline of products originates from its proprietary Macrocyclic Template Chemistry (MATCH™) technology platform, which enables the construction of synthetic libraries of drug-like, macrocyclic compounds in a predictable and efficient manner. MATCH™ is a drug design and medicinal chemistry platform which exploits the potential of macrocycles, a distinct compound class that displays the favorable characteristics exhibited by large biomolecules, while maintaining the benefits typically associated with small molecule drugs. Outside of Tranzyme's current development focus, MATCH™ has broad applicability in the treatment of other diseases that involve hormones, peptides, ion channels, or protein-protein interaction pathways.
Tranzyme’s objective is to develop and bring to market products to treat acute and chronic GI motility disorders that are not satisfactorily or safely treated with current therapies and that represent significant market opportunities.
Tranzyme's strategy is to license certain rights to its drug development programs once proof of concept in man is achieved, or when a program may benefit from the research, development and commercialization capabilities of a partner. Through these strategic partnerships, Tranzyme intends to balance risk while preserving the potential for significant returns.